Orladeyo™ (berotralstat) – New orphan drug approval
December 3, 2020 - BioCryst Pharmaceuticals announced the FDA approval of Orladeyo (berotralstat), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.
Download PDF
